Vaxart entered into Modification No. 7 to its ATI-RRPV Project Award Agreement to continue its Phase 2b comparative study of an oral COVID-19 vaccine against an FDA-approved mRNA comparator. The BARDA-funded award, administered by Advanced Technology International, now provides approximately $345 million in total available funding, including about $68 million in firm fixed price amounts. The modification reflects an approximate $116 million reduction tied to a prior BARDA-ordered enrollment cut and releases around $29 million to complete the trial and exploratory analyses.
Agreement details:
- Agreement type: Modification to ATI-RRPV Project Award Agreement (BARDA-funded clinical trial award)
- Counterparty: Advanced Technology International
- Signed / Effective: Jun 22 2026 / same
- Duration / Termination: At will
- Reason: Advance Phase 2b oral COVID-19 vaccine trial
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.